CTAD and ADDF Unite to Accelerate Alzheimer’s Innovation
NEW YORK, N.Y., June 16, 2026 The Clinical Trials on Alzheimer’s Disease (CTAD) Conference and the Alzheimer’s Drug Discovery...
EMA approval
Advertisement
UCB Reports Positive KYGEVVI Outcomes in TK2d Patients
BRUSSELS, Belgium, June 17, 2026 UCB has announced the publication of two significant peer-reviewed studies in Brain Communications demonstrating...
Teva Launches AHZANTIVE Biosimilar to Eylea Across Europe
TEL AVIV, Israel, June 4, 2026 Teva Pharmaceutical Industries Ltd. has announced the European launch of AHZANTIVE® (aflibercept), an...
Pixee Medical Knee+ NexSight Wins FDA 510(k) Clearance
BESANÇON, France, April 28, 2026 Pixee Medical has announced that its next-generation augmented reality (AR) surgical navigation system, Knee+...
Taiho Zipalertinib NDA Accepted by FDA for NSCLC
PRINCETON, New Jersey, USA / TOKYO, Japan / CAMBRIDGE, Massachusetts, USA, April 28, 2026 Taiho Oncology, Taiho Pharmaceutical, and...
Advertisements
VectorY Therapeutics Secures EMA and MHRA Approval for VTx-002 Trial
AMSTERDAM, Netherlands & BOSTON, Massachusetts, USA, April 28, 2026 VectorY Therapeutics has announced that it has received authorization from...
SQ Innovation Lasix ONYU Gains CE Mark EMA Review
BURLINGTON, Massachusetts, USA, April 28, 2026 SQ Innovation has announced that its drug-device combination therapy Lasix® ONYU has achieved...
Novo Nordisk Secures EMA Approval for Wegovy Delivery Flexibility
Bagsværd, Denmark | April 9, 2026 Novo Nordisk has announced that the European Medicines Agency (EMA) has approved an...
Sanofi Rezurock Wins EU Approval for Chronic GvHD
PARIS, France, March 31, 2026 Sanofi has received European Commission approval for Rezurock® (belumosudil) for the treatment of chronic...
Abbisko Irpagratinib Gains EMA Orphan Drug Status
SHANGHAI, China, March 31, 2026 Abbisko Therapeutics has announced that its investigational FGFR4 inhibitor irpagratinib (ABSK-011) has been granted...
Advertisement
